New Machine Learning Models Improve Prediction of Thrombosis and Bleeding in Cancer – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Danielle Carole Roy et al, adding:
”Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer (AVERT trial analysis)
Using data from 514 ambulatory cancer patients in the AVERT trial, machine-learning models combining biomarkers and genetics predicted both venous thromboembolism (AUC 0.92) and clinically relevant bleeding (AUC 0.90).
VTE risk tracked with factor V Leiden and certain cancers, while bleeding risk tracked with cardiac and inflammatory markers.
The sample stayed modest.
Title: Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer: analysis from the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients trial
Authors: Danielle Carole Roy, Tzu-Fei Wang, Philip Wells, Ranjeeta Mallick, Dylan Burger, Marc Carrier, Steven Hawken
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 25, 2026, 00:07Muhammad Ali Khan: Using EHR Data to Predict Fibrotic Progression in PV and ET
-
Aug 25, 2026, 00:06Michael R. Scoma: The Vascular Dimension of Long COVID
-
Aug 24, 2026, 23:40Vimee Bindra: Your Period May Be Trying to Tell You Something
-
Aug 24, 2026, 23:30R. P. Singh: Hemophilia and HIV Relationship
-
Aug 24, 2026, 23:12Marta Velia Antonini: Hemolysis in ECMO – More Than Just a Laboratory Finding
-
Aug 24, 2026, 18:13Chokri Ben Lamine: Ruxolitinib – Comprehensive Clinical Reference
-
Aug 24, 2026, 18:10Yazan Abou-Ismail: ClotCast Episode 8 – What Are Platelets?
-
Aug 24, 2026, 17:11Kristin Neves: Which Hematologic Parameters Guide Your PV Treatment Decisions?
-
Aug 24, 2026, 17:00Should Hormone Therapy Automatically Stop After a Thrombosis? – Thrombosis Canada